Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients
| Autor: | Hidenobu Tanihara, Jin Tahara, Takahiro Kawaji, Nina Sagara, Yasuya Inomata, Mikiko Fukushima, Ryuhei Hara |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Fovea Centralis medicine.medical_specialty Porphyrins genetic structures medicine.medical_treatment Visual Acuity Angiogenesis Inhibitors Photodynamic therapy Antibodies Monoclonal Humanized Macular Degeneration Cellular and Molecular Neuroscience Asian People Ophthalmology Age related Humans Medicine Intravitreal bevacizumab Aged Retrospective Studies Aged 80 and over Clinical Trials as Topic Photosensitizing Agents Choroid business.industry Antibodies Monoclonal Verteporfin Recovery of Function Middle Aged Macular degeneration medicine.disease eye diseases Sensory Systems Bevacizumab Vitreous Body Treatment Outcome Photochemotherapy Female sense organs Injections Intraocular business Tomography Optical Coherence Follow-Up Studies medicine.drug |
| Zdroj: | Graefe's Archive for Clinical and Experimental Ophthalmology. 248:931-936 |
| ISSN: | 1435-702X 0721-832X |
| Popis: | To compare 12-month results of two single initial treatments--photodynamic therapy with verteporfin alone (PDT group), and this therapy combined with intravitreal bevacizumab (IVB) (COMB group)--for neovascular age-related macular degeneration (AMD), not including patients with polypoidal choroidal vasculopathy (PCV) who were presumed to have AMD.This retrospective study evaluated 23 eyes in the PDT group and 22 eyes in the COMB group. IVB (1.25 mg) was administered within 2 weeks after PDT. Main outcome measures were best-corrected visual acuity (VA), central foveal thickness by optical coherence tomography, and number of treatments.At month 12, the PDT group had gained 0.7 letter mean VA and the COMB group, 8.8 letters (P = 0.04). Ten eyes (43%) in the PDT group and 19 eyes (86%) in the COMB group received only one treatment, and significant difference was found (P = 0.005). No severe ocular or systemic safety concerns were discovered.Our 12-month results of PDT combined with IVB for Japanese patients with AMD without PCV appeared to be more effective than those of PDT alone with fewer treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink